Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Caliper Technologies - CALP -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (109)	10/3/2007 1:31:47 PM
From: Steve Lokness	Respond to of 114

Tuck; Of course, CALP is just kind of sitting there, share price-wise. One does wonder how XGEN would have done independently. I'd guess a little better than CALP has in that time frame. Ya, I suspect you are right. But then again, that suggest CALP did a wise buy? The news this morning is not much and my gut says it will be followed by something else. Not sure what. Someone on Yahoo answered your question on the lawsuit; the judge sent them back into their corners to prepare better - according to the post. (The link for this ruling is 64 pages long). If Anticancer wasn't prepared enough - my guess is that there is an agreement before they come back? And this from your post; More than 70% of major pharmaceutical companies, and 60% of major biotech companies, now hold a license to the Caliper Optical Imaging Patent Suite, and smaller biotechs are following suit in increasing numbers." This has to be worth something in some way or another I would think. No? Good Investing; steve

To: tuck who wrote (109)	11/7/2011 1:59:27 AM
From: tuck	Respond to of 114

Very old news (3.5 years!) but the AntiCancer litigation was finally settled through cross-licensing: >>HOPKINTON, Mass. and SAN DIEGO, Calif., February 26, 2008 -- Caliper Life Sciences (NASDAQ: CALP) and AntiCancer, Inc. today announced that they have entered into an agreement to establish a cross-licensing relationship and end all outstanding patent litigation between the two companies. Under the new cross-licensing arrangement, Caliper acquires the right to sublicense AntiCancer’s fluorescent protein optical imaging patents to third-parties, alongside Caliper’s own portfolio of in vivo fluorescent and bioluminescent optical imaging patents; AntiCancer acquires the right to sublicense Caliper’s optical imaging patents, in the field of fluorescent protein imaging, to a specified annual number of third parties throughout the life of the agreement, alongside AntiCancer’s own fluorescent protein optical imaging patents. In addition, each company receives a royalty free license from the other for internal and contract research operations. The agreement further strengthens Caliper’s intellectual property estate specifically extending the range of fluorescent protein optical imaging rights available to customers. Focused on delivering a range of optical imaging technologies to meet the needs of the pharmaceutical and biotech industries, Caliper continues to strive to enable unsurpassed research flexibility specifically in the areas of cancer research and other critical therapeutic areas. Under the cross-license arrangement, Caliper and AntiCancer will share in any revenues generated by the licensing of their proprietary imaging technologies in the field of fluorescent protein imaging. No other payments will be made for either the settlement or cross-licensing agreements. Further financial details of the cross-licensing arrangement were not disclosed. The companies also expect to enter into an OEM distribution agreement under which Caliper will market and sell certain mouse and cell lines developed by AntiCancer for use in fluorescent protein-based optical imaging experiments. “This settlement and the resulting alignment between Caliper and AntiCancer represent a major step forward for the in vivo molecular imaging community,” said Kevin Hrusovsky, President and CEO of Caliper. “In addition to our unique position in bioluminescent and fluorescent conjugate imaging, the cross-licensing arrangement enables Caliper to provide our existing and prospective license customers with a broader suite of intellectual property rights for optical imaging with fluorescent proteins. This should greatly enhance the clarity and breadth of protection associated with these patents. We also look forward to the opportunity to expand our reagents business by marketing and selling fluorescent protein cell lines developed by AntiCancer.” “We are very pleased with the opportunity to work collaboratively with Caliper, the clear leader in terms of the number of pre-clinical optical imaging instruments placed in the market,” said Robert Hoffman, Ph.D., President and CEO of AntiCancer. “AntiCancer is very pleased to have an outstanding partner such as Caliper to greatly enhance this pioneering fluorescent imaging technology. AntiCancer’s mission has always been the development of technologies for the treatment and cure of cancer, and we look forward to furthering this mission through the combined innovative power of AntiCancer and Caliper.” << Cheers, Tuck